Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- ASKA Begins Japan PIII for Relugolix Combo Drug
December 17, 2024
- Kyorin Licenses Novel OSA Treatment from Bayer
December 17, 2024
- Strattera and All Generic Versions Now under Supply Restrictions in Japan
December 17, 2024
- COVID Jab Kostaive Gets EMA Backing: Meiji
December 17, 2024
- Mochida Ties Up with Kuhnil to Market Epadel in South Korea
December 17, 2024
- Takeda Sees Up to US$20 Billion Sales Potential with 6 Late-Stage Assets
December 16, 2024
- Teijin Seek Japan Approval for Ascendis’ Hypoparathyroidism Drug
December 16, 2024
- Amgen Japan Marks “Significant Milestone” with Tepezza Release, Eyes More Launches
December 16, 2024
- BMS Files Augtyro for NTRK-Positive Solid Tumors in Japan
December 16, 2024
- EA Pharma Bags Japan, Asia Rights to Newron’s Schizophrenia Drug
December 16, 2024
- Mitsubishi Tanabe to Reinstate CEO Role, with Tsujimura at Its Helm
December 16, 2024
- BrightPath/Cellistic Pair Up for PI Trial of iPSC-derived NKT Cell
December 16, 2024
- RaQualia’s Acid Reducer Now Available in 5 Latin American Countries
December 13, 2024
- Daiichi Kicks Off PIII Quizartinib Study for FLT3-ITD Negative AML
December 12, 2024
- Kyowa Kirin to Globalize Research Organization after Orchard Buy
December 12, 2024
- Santen’s Glaucoma Drug Accepted for Review in Korea, Vietnam
December 12, 2024
- Eisai’s Gout Drug Urece Wins Nod in China
December 12, 2024
- ViiV to Hone In on Long-Acting Treatments for HIV: Japan President
December 11, 2024
- Ono Set for Japan Filing of SK Bio’s Epilepsy Med in FY2025
December 11, 2024
- It’s High Time to Rethink Market Price-Based Revision Scheme: Chugai CEO
December 10, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…